synthesis of isotopically labelled [ 14 c]zt-1, [d 3 ]zt-1 & (-)-[d 3 ]huperzine a, a new...
TRANSCRIPT
Synthesis of isotopically labelled [14C]ZT-1,
[d3]ZT-1 & (-)-[d3]huperzine A, a new generation of acetylcholinesterase inhibitors
Dr Sean KitsonШОН КИТСОН
Objective
• This lecture will focus on a brief introduction to carbon-14
• Leading onto synthetic strategies towards labelling (-)-huperzine A derivatives with 14C and 2H
cpres/v1b/ca/1998-08/ 3
A Brief Introduction to 14C
Discovery of 14CMartin Kamen & Sam Ruben (27-FEB-1940)
T1/2 ~ 5730 Years
Production of 14C
ReactorBombardment by Neutrons
Nitrogen 147 Protons7 Neutrons
N
PP
Radioactiveatom
Carbon 146 Protons8 Neutrons
Decay to stable daughter nuclide
Nitrogen 147 Protons7 Neutrons
N
ß-
P
ß-
P
14N7 + 1n0 → 14C6 + 1H1
14C Starting Materials
Ba(OH)2
Barium 14C carbonate staircaseOH
C14
NH
O
OHF3C
OH
Cl
OH
OHOMe
MeO
OMe
NCH3
OH
OH
C14
H
C14 OH
O
Ba14CO3
14C6
14CO2
14CH3OH
14CH3I
H14CHO
Cu14CN
K14CN
14C6
AA
14C
H314CO
14CHH14C
[14C]PEPTIDES
R T Brown et al. JLCR 2009, 52, 567-570
S L Kitson, S Jones et al. JLCR 2010, 53, 140-146
S L Kitson. JLCR 2007, 50, 290-294S L Kitson, E Knagg. JLCR 2006, 49, 517-531
[14C]Apomorphine [14C]Combretastatin A-1
[14C]XEN-D0401
[14C]Acetylenes
14C LabellingWhen designing a 14C labelled synthesis it is important to consider the following:
• Identify simple starting materials from the barium 14C carbonate ‘staircase’ which are commercially available or alternatively easily made
• Plan, develop and execute the synthetic methodology to the final drug substance. This approach can often restrict the position of the label in the drug and will cause a change in the drug purity profile from the original laboratory synthesis route
• Locate a biologically stable position for the 14C labelS L Kitson ‘Accelerated Radiochemistry’,PMPS Manufacturing 2010, 68-70
14C Drug Molecules14C Labelled drugs are used in human mass
balance or AME studies to evaluate:• Mass balance and the routes of elimination• Identify circulatory and excretory metabolites• Determination of clearance mechanisms• To determine the exposure of parent compound
and its metabolites• Used to validate animal species used for
toxicological testing• To explore whether metabolites contribute to the
pharmacological / toxicological effects of the drug
C Prakash et al. Biopharm. Drug Dispos; 2009, 30, 185-203
(-)-Huperzine & ZT-1
(-)-Huperzine A• (-)-Huperzine A is a naturally occurring Lycopodium
alkaloid found in an extract from the club moss Huperzia serrata
• (-)-Huperzine A is a potent, selective and reversible inhibitor of acetyl cholinesterase, the enzyme that breaks down or degrades acetylcholine
• (-)-Huperzine A is currently a prescription medication in China for the treatment of Alzheimer's Disease
4
NH
CH3
O
NH2
CH3
6
11
13
14
1
2
35
12
8
9
7
10
C M Yu et al. Canadian J Chem 1986, 64, 837-839D L Bai et al. Curr. Med. Chem; 2000, 7, 355-374
ZT-1: Pro-drug for (-)-Huperzine AA Novel Acetylcholinesterase Inhibitor
CHO
OH
Cl OMe
NH
CH3
O
NH2
CH3
NNO
Cl
H
MeOH O
H
CH3
CH3 in vivo progressive hydrolysis
active compound, (-)-huperzine A
+
Pro-drug ZT-1 metabolite, 5-chlorovanillin
exocyclic E-double bond
pyridin-2-one ring
hydrogen bond
R
bicyclo[3.3.1] double bond
L Leman, S L Kitson, R T Brown et al. JLCR 2011 (in press)
ZT-1 Implant
POLYMER DRUG
BLENDING
EXTRUSION
PLGA ZT-1
ZT-1 IMPLANT
S. Capancioni et al. Preparation of a sustained-release implant of the acetylcholinesterase inhibitor ZT-1 by hot-melt extrusion (HME) and evaluation in rats Debiopharm (April 2006)
ZT-1 implant offers the following advantages over oral ZT-1:
• Once-a-month dosing
• Implant-controlled progressive increase in (-)-huperzine A plasma levels
• Sustained plasma levels
• A prolonged release of the (-)-huperzine A over several weeks
S. Capancioni et al. Preparation of a sustained-release implant of the acetylcholinesterase inhibitor ZT-1 by hot-melt extrusion (HME) and evaluation in rats Debiopharm (April 2006)
[14C] & [d3] - Targets
NH
CH3
O
NH2
D3C
NH
CH3
O
N
OH
ClMeO
CH3
NH
CH3
O
N
OH
ClMeO
D3C
*
(-)-[d3]Huperzine-A [14C]ZT-1 [d3]ZT-1
Synthesis of [14C]ZT-114C
labelling
Schiff base
OH
Cl
O
OMeH
NH
CH3
O
CH3 N
OH
ClMeO
*
NH
CH3
O
CH3
NH2
*
[14C]ZT-1
+
Schiff baseformation
(-)-Huperzine A 5-Chloro[U-14C]vanillin
Retro-synthetic pathwayOH
Cl
O
OMeH
OP
OMe
OP
I
OH
*
OP
OMeOHC
* **
*
[14C]-1
deprotection
halogenation
[14C]-7 A B
C
alkoxy de-halogenationortho-directed iodination
ortho-directed formylation
14C SynthesisOH
OH
OMe
Cl
O
H
OH
OMe
O
H
OMOM
OMe
OMOM
OMe
O
H
OMOM OMOM
I
* * *
* *
**
[14C]-1
[14C]-7[14C]-6
[14C]-2 [14C]-3
[14C]-4 [14C]-5
NaH/DMF
MOM-Cl
n-BuLi
I2
CuBr/DMF
NaOMe/MeOH
n-BuLi
DMF
HCl/MeOH ICl / CH2Cl2
NaHCO3
Step 1 Step 2
Step 5
Step 3 Step 4
Step 6
* = U-14C
[14C]ZT-1
NH
CH3
O
NH2
CH3
OH
Cl
O
OMeH
NH
CH3
O
CH3 N
Cl
OH
MeO
*
*
(-)-Huperzine A [14C]ZT-1
EtOH, heat
[14C]-7
Step 7
Synthesis of
[d3]ZT-1 & (-)-[d3]huperzine
Retro-synthesis
NH
CH3
O
NH2
D3C
N
CH3
OMe
D3C CO2H
D3C PPh3
N
CH3
OMe
CO2MeO
Curtius rearrangement
Wittig
+
(-)-[d3]Huperzine A
(+)-8
isomerisation
N
CH3
CO2Me
OMe
O
N
CH3
CO2Me
OMe
CD3
N
CH3
CO2Me
OMe
D3C
N
CH3
CO2Me
OMe
CD3
PhS
.
Ph3P+CH2CD3.Br -
basePhSH, AIBN
(+)-8 [d3]-9
[d3]-10
Step 9 Step 10
Ph3P
D3CCH2Br
Step 8
Z > E
E > Z
via
radical
hydrogen abstraction from PhSHaddition of PhS. to cis-double bond180 degrees rotationejection of thiyl radical by beta-scission
Synthesis of (-)-[d3]huperzine A
C. Ferreri et al. Chem. Commun; 1999, 407-408
N
CH3
CO2Me
OMe
D3C
N
CH3
OMe
NHCO2MeD3C
NH
CH3
O
NH2
D3C
N
CH3
OMe
D3C CO2H
(-)-[d3]huperzine A
NaOH (PhO)2PON3 / Et3N
MeOH
TMS-I
[d3]-10[d3]-11
[d3]-12
Step 11
Step 12
Step 13
E > Z
MeOH
Synthesis of (-)-[d3]huperzine A
G A Olah, J. Org. Chem; 1979, 44, 1247-1251
S-I Yamada et al. J. Am. Chem. Soc; 1972, 94, 6203
NH
CH3
O
NH2
D3C
NH
CH3
O
D3C N
OH
ClMeO
Cl
OH
OMeH
O
NH
CH3
O
D3C NH
OH
ClMeO
NH
CH3
O
D3C NH
OH
ClMeO
[d3]-huperzine A [d3]ZT-1
Step 14
NaBH4
reduced-[d3]ZT-1 reduced-[d3]ZT-1.HCl
.HClMeOH HCl/Et2O
Step 15 Step 16
EtOH, heat
Synthesis of [d3]ZT-1&
reduced-[d3]ZT-1
Conclusion
• [14C]ZT-1 was isolated with a radiochemical purity of >98%area and a gravimetric specific activity of 129 μCi/mg in a seven step synthesis starting from [U-14C]phenol in 7% yield
• Subsequently, the deuterium labelled target
(-)-[d3]huperzine A was achieved in 6 steps with an overall yield of 15% and gave an isotopic distribution of
d2 (1.65% huperzine A) and d3 (97.93% huperzine A) with a chemical purity of 98.5%
Conclusion
• Condensation of the substrate (-)-[d3]huperzine A with 5-chlorovanillin gave the Schiff’s base [d3]ZT-1 in a chemical yield of 80%
• Reduction of the Schiff’s base gave reduced-[d3]ZT-1 which was converted into the hydrochloride salt with an isotopic distribution of d2 (1.60%) and d3 (98.02%)
Almac’s Radiochemistry Laboratory
Almac’s Radiolabelling Team
Non GMPNon GMPAPI ManufactureAPI Manufacture
Drug ProductDrug ProductManufactureManufacture
GMP APIGMP APIManufactureManufacture
Form.Form.Dev.Dev.
Clinical Clinical PackagingPackaging
and Labellingand Labelling
RadioRadioLabellingLabelling
Solid State &Solid State &Analytical Analytical ServicesServices
StabilityStability
BiomarkersBiomarkers& &
DiagnosticsDiagnosticsDiscoveryDiscoveryResearchResearch
IVRSIVRS
Northern Ireland HQ (32 acre siteNorthern Ireland HQ (32 acre site))www.almacgroup.comwww.almacgroup.com
Confidential © Almac Group 2010
North American HQ (40 acre site)North American HQ (40 acre site)www.almacgroup.comwww.almacgroup.com
Clinical Clinical Packaging & Packaging & DistributionDistribution
Admin & Clinical
Admin & Clinical
Tech Facility
Tech Facility
Solid State & Solid State & Analytical Analytical Services Services
Thank you / Спасибо
The hexagonal shapes denote the famous Giant’s Causeway rock in Northern Ireland – these shapes also connect to the benzene ring used in science